Hanwha Life Insurance’s board approved a 440 billion won acquisition of a 50.54% controlling stake in Acuon Capital on September 30. The South Korean credit finance company is currently held by global private equity firm EQT Partners. Centroid Investment Partners will participate as a financial investor alongside Hanwha Life.
The deal adds credit finance and a savings banking operation to a group that already spans life insurance, general insurance, asset management, and securities. Regulatory approval is pending and no completion date has been announced.
Acuon Capital reported approximately 4.6 trillion won in assets in the first half of 2026 and wholly owns Acuon Savings Bank, which held around 5.1 trillion won over the same period.
Hanwha Life plans to merge Acuon Savings Bank with its existing Hanwha Savings Bank, creating a combined savings banking operation with roughly 6.5 trillion won in assets. That brings deposit-taking and lending exposure into a group whose financial risks have previously centred on long-term insurance liabilities and investment portfolios.
The broader savings banking sector is recovering but still under pressure. The Korea Federation of Savings Banks reported that 79 domestic savings banks recorded a combined net profit of 765.8 billion won in the first half of 2026, with the sector-wide delinquency rate at 6.3% at end-June – down from 6.7% the previous quarter.
Read next: Hana Financial weighs third capital injection for non-life arm
The Korea Deposit Insurance Corporation (KDIC) has a direct financial interest in how this acquisition unfolds.
The KDIC holds a 10% stake in Hanwha Life, a legacy of the 3.55 trillion won in public funds it injected into the then-insolvent Daehan Life Insurance between 1999 and 2001, following the 1997 Asian financial crisis. It has been steadily selling down that stake ever since, recovering funds through Hanwha Life’s 2010 IPO and subsequent block deals.
The problem is timing. The KDIC’s Bond Redemption Fund is set to expire at the end of 2027, and the corporation has built the sale of its entire remaining Hanwha Life stake into its 2026 budget. According to Seoul Economic Daily, it had set a target sale price of 5,000 won per share. Hanwha Life’s share price at the time of reporting was around 4,845 won. Industry sources cited in the same report noted that full public fund recovery would require a price closer to 10,000 won per share – a figure the stock has not been near.
A large acquisition that adds risk-weighted assets and compresses Hanwha Life’s K-ICS solvency ratio is, in plain terms, a share price problem for the KDIC.
The KDIC has been publicly clear about the pressure it faces. A senior government official told Seoul Economic Daily: “The Bond Redemption Fund will be liquidated next year without extension.”
A financial industry source added: “If we fixate on the 10,000 won price, we will inevitably face criticism for failing to complete the recovery even by the time the Bond Redemption Fund is liquidated.”
AM Best, in a July 2026 report on Hanwha General Insurance – the group’s non-life arm – noted that negative rating actions could follow if balance sheet strength deteriorates at either the subsidiary or parent level. The report also confirmed that Hanwha Life Financial Services, a sales-specialised subsidiary, serves as the group’s primary distribution channel for affiliated general agent partners.
For brokers operating within that structure, any sustained pressure on the parent’s capital position is relevant to the stability of subsidiary support and co-distribution arrangements.
The Acuon deal is not Hanwha Life’s only large capital commitment.
On the same day the board approved the Acuon acquisition, it also committed 250 billion won to a capital raise for Hanwha Investment & Securities. Hanwha Asset Management is contributing another 250 billion won, bringing that raise to 500 billion won total. The securities arm is also weighing up to 400 billion won in hybrid capital securities – a potential programme of 900 billion won.
Beyond that, the Korea Times reported that Hanwha Life joined Heungkuk Life Insurance and Korea Investment Holdings in submitting a final bid for KDB Life Insurance. Investment banking sources noted this came as a surprise given Hanwha’s existing financial commitments. Bidders estimate KDB Life could require up to 1 trillion won in post-acquisition capital injections.
Hanwha Life also completed the acquisition of a 75% stake in US-based brokerage Velocity Clearing in July 2025, becoming the first Korean insurer to enter the US securities market.
The Financial Services Commission (FSC) designated Hanwha as one of eight non-holding financial conglomerates for 2026, requiring consolidated capital adequacy reporting and group-wide risk management under the Act on the Supervision of Financial Conglomerates.
Read next: South Korean insurer consolidation narrows the field for brokers
No changes to Hanwha Life’s insurance distribution have been announced as part of the Acuon transaction.
What has changed is the scale of concurrent capital demands on a group that is now adding risk-weighted assets from several directions at once. The KDIC needs a healthy Hanwha Life share price. AM Best is watching balance sheet trends at the parent level. Regulators are monitoring group-wide risk.
Brokers with Hanwha on their panels are dealing with a different kind of counterparty than a standalone insurer – one whose capital allocation decisions extend well beyond the insurance business.
